Neflamapimod Improves Episodic Memory in Early Alzheimer’s Patients in Phase 2a Trial

Neflamapimod Improves Episodic Memory in Early Alzheimer’s Patients in Phase 2a Trial
Investigational therapy Neflamapimod led to significant improvements in episodic memory function in patients with early Alzheimer’s disease, results from EIP Pharma’s Phase 2a clinical trial show. “Significant unmet need exists for improved Alzheimer’s treatments which is why we are so encouraged by these data demonstrating neflamapimod’s potential to improve memory function in patients with Alzheimer’s disease,” John

Knowledge is power when living with alzheimers.

Get access to the web’s leading Alzheimer news & insights for as little as 16¢/day.
Subscribe or to access all post and page content.

One comment

  1. Neflamapimod could be a terribly interesting drug for Alzheimer patients.Its mode of action is much more satisfactory than that of monoclonals: it corrects a key metabolic disturbance met with in Alzheimer (hyperactivity of P38 alpha kinase ) which induces synaptic dysfunction. Experimentally its activity has also been demonstrated at the hippocampal level. If I were a big pharma firm, I would immediately try to buy the company behind this drug.

Leave a Comment

Your email address will not be published. Required fields are marked *